&lt;p&gt;Structural Genomics of &lt;em&gt;repA, repB1&lt;/em&gt;-Carrying IncFIB Family pA1705-&lt;em&gt;qnrS&lt;/em&gt;, P911021-&lt;em&gt;tetA&lt;/em&gt;, and P1642-&lt;em&gt;tetA&lt;/em&gt;, Multidrug-Resistant Plasmids from&lt;em&gt; Klebsiella pneumoniae&lt;/em&gt;&lt;/p&gt;

Nazir, Amina; Zhao, Yachao; Li, Manli; Manzoor, Rakia; Tahir, Rana Adnan; Zhang, Xianglilan; Qing, Hong; Tong, Yigang

doi:10.2147/idr.s228704

Cited by 16 publications

(11 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past three years, the SARS-CoV-2 pandemic challenged the world and contributed further to the multidrug-resistance crises, due to the prophylactic administration of antibiotics in avoid to secondary infections [ 10 ]. The MDR becomes a worldwide public health issue since there are often no (chemical) antibiotics available, mainly for secondary infections [ 11 ]. Therefore, it is crucial to evaluate the morbidity caused by secondary infections and consider alternative clinical approaches to the currently used therapies [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

As of 29 July 2022, there had been a cumulative 572,239,451 confirmed cases of COVID-19 worldwide, including 6,390,401 fatalities. COVID-19 patients with severe symptoms are usually treated with a combination of virus- and drug-induced immuno-suppression medicines. Critical clinical complications of the respiratory system due to secondary bacterial infections (SBIs) could be the reason for the high mortality rate in COVID-19 patients. Unfortunately, antimicrobial resistance is increasing daily, and only a few options are available in our antimicrobial armory. Hence, alternative therapeutic options such as enzymes derived from bacteriophages can be considered for treating SBIs in COVID-19 patients. In particular, phage-derived depolymerases have high antivirulent potency that can efficiently degrade bacterial capsular polysaccharides, lipopolysaccharides, and exopolysaccharides. They have emerged as a promising class of new antibiotics and their therapeutic role for bacterial infections is already confirmed in animal models. This review provides an overview of the rising incidence of SBIs among COVID-19 patients. We present a practicable novel workflow for phage-derived depolymerases that can easily be adapted for treating SBIs in COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are few reports on characterization of IncFIB replicon 11 and IncFIB single-replicon plasmids. 19 In this work, a repB sequence-based scheme was proposed for grouping IncFIB replicon into seven primary types and further into 70 subtypes. Furthermore, a comprehensive comparative genomics analysis of 11 IncFIB-4.1/4.2 single-replicon plasmids (including nine ones sequenced in this work) provided a deeper insight into diversification and evolution of IncFIB-4.1/4.2 single-replicon plasmids.…”

Section: Introductionmentioning

confidence: 99%

IncFIB-4.1 and IncFIB-4.2 Single-Replicon Plasmids: Small Backbones with Large Accessory Regions

Xu¹,

Jing²,

Hu³

et al. 2022

IDR

View full text Add to dashboard Cite

Purpose To establish a typing scheme for IncFIB replicon and to dissect genomic features of IncFIB-4.1/4.2 single-replicon plasmids. Methods A total of 146 representative fully sequenced IncFIB-replicon-containing plasmids were selected to construct a phylogenetic tree of repB IncFIB sequences. A collection of nine IncFIB-4.1/4.2 single-replicon plasmids from China were fully sequenced here and compared with the first sequenced IncFIB-4.1/4.2 single-replicon plasmids from GenBank to dissect their genomic diversity. Results In this study, a repB sequence-based scheme was proposed for grouping IncFIB replicon into seven primary types and further into 70 subtypes. A collection of nine IncFIB-4.1/4.2 single-replicon plasmids were fully sequenced here and compared with the first sequenced IncFIB-4.1/4.2 single-replicon plasmids from GenBank. These 11 plasmids had small backbones and shared only three key backbone markers repB together with its iterons, parABC , and stbD . Each plasmid contained one large accessory region (LAR) inserted into the backbone, and these 11 LARs had significantly distinct profiles of mobile genetic elements (MGEs) and resistance/metabolism gene loci. Antibiotic resistance regions (ARRs; the antibiotic resistance gene-containing genetic elements) were found in seven of these 11 LARs. Besides resistance genes, ARRs carried unit or composite transposons, integrons, and putative resistance units. IncFIB-4.1/4.2 single-replicon plasmids were important vectors of drug resistance genes. This was the first report of three novel MGEs: In1776, Tn 6755 , and Tn 6857 . Conclusion Data presented here provided a deeper insight into diversity and evolution of IncFIB replicon and IncFIB-4.1/4.2 single-replicon plasmids.

show abstract

“…It is an opportunistic and ubiquitous bacterium that causes nosocomial and community-acquired infections including septicemia, pneumonia and meningitis etc. 1 It is one of the bacteria that causes high mortality rate in immuno-compromised patients. 2 Its widely spread antibiotic resistance in all over the world pose a major challenge to public health.…”

Section: Introductionmentioning

confidence: 99%

Characterization and Genomic Analysis of a Novel Drexlervirial Bacteriophage IME268 with Lytic Activity Against Klebsiella pneumoniae

Nazir¹,

Qi²,

Shi³

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

Introduction Klebsiella pneumoniae , a multidrug resistant bacterium, that causes nosocomial infections including septicemia, pneumonia etc. Bacteriophages are potential antimicrobial agents for the treatment of antibiotic resistant bacteria. Methods and Results In this study, a novel bacteriophage IME268 was isolated from hospital sewage against clinical multi-drug resistant Klebsiella pneumoniae . Transmission electron microscopy and genomic characterization of this phage exhibited it belongs to the Webervirus genus, Drexlerviridae family. Phage IME268 possessed a double-stranded DNA genome composed of 49,552bp with a GC content of 50.5%. The phage genome encodes 77 open reading frames, out of 44 are hypothetical proteins while 33 had assigned putative functions. No tRNA, virulence related or antibiotic resistance genes were found in phage genome. Comparative genomic analysis showed that phage IME268 has 95% identity with 87% query cover with other phages in NCBI database. Multiplicity of infection, one step growth curve and host range of phage were also measured. Conclusion According to findings, Phage IME268 is a promising biological agent that infects Klebsiella pneumoniae and can be used in future phage therapies.

show abstract

<p>Structural Genomics of <em>repA, repB1</em>-Carrying IncFIB Family pA1705-<em>qnrS</em>, P911021-<em>tetA</em>, and P1642-<em>tetA</em>, Multidrug-Resistant Plasmids from<em> Klebsiella pneumoniae</em></p>

Cited by 16 publications

References 54 publications

Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients

Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients

IncFIB-4.1 and IncFIB-4.2 Single-Replicon Plasmids: Small Backbones with Large Accessory Regions

Characterization and Genomic Analysis of a Novel Drexlervirial Bacteriophage IME268 with Lytic Activity Against Klebsiella pneumoniae

Contact Info

Product

Resources

About